All In Biotech

Drug Trial Radar · NCT07251062

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.

A Phase II/III Study to Evaluate the Efficacy and Safety of SYS6010 in Combination With SG001 With or Without 5-FU/Capecitabine in Subjects With First-Line Advanced/Metastatic Esophageal Squamous Cell Carcinoma.

Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 737 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

737

Planned (sponsor's estimate)

Start

Dec 30, 2025

Primary completion

Dec 30, 2029

Study completion Dec 30, 2030

Sponsor

Sponsor type
Industry
First posted
Nov 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter phase 2/3 clinical study to evaluate the efficacy and safety of SYS6010 plus SG001±5-FU/Capecitabine as first-line treatment, in patients with advanced/metastatic esophageal squamous cell carcinoma.

Conditions

  • Esophageal Squamous Cell Carcinoma

Interventions

  • SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)Drug

    SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker. SG001 is a recombinant, fully human, anti-PD-1 monoclonal antibody. Capecitabine: Capecitabine is for oral administration. 5-FU: Administration at the conventional dosage.

  • Investigator's choice of SOCDrug

    1. Camrelizumab + Cisplatin + Paclitaxel 2. Tislelizumab + Cisplatin + Paclitaxel 3. Tislelizumab + Cisplatin + 5-FU/Capecitabine

  • SYS6010+SG001Drug

    SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker. SG001 is a recombinant, fully human, anti-PD-1 monoclonal antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PhaseII(safety leadrun-in stage): DLT; Description: Dose-limiting toxicityTime frame: 28 days
  2. PhaseII(safety run-inlead-in stage): AETime frame: From the signing of the informed consent form until 90 days after the last dose.
  3. PhaseII(safety leadrun-in stage): MTD;Time frame: After phase II saftysafety run-inlead-in stage and dose expansion stage. Approximately 4 months.
  4. PhaseII(safety run-inlead-in stage): RP2DTime frame: After phase II saftysafety run-inlead-in stage and dose expansion stage. Approximately 4 months.
  5. PhaseII(Randomized treatment stage): ORR per RECIST v1.1Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
  6. PhaseIII: PFS-ICRTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years
  7. PhaseIII: OS;Time frame: Through study completion, up to approximately 5 year.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.